icon
icon
icon
icon
Upgrade
icon

Roche (RHHBY.US) enters near-$900M collaboration to develop autoimmune disease therapies

AInvestWednesday, Dec 4, 2024 2:40 am ET
1min read

COUR Pharmaceuticals announced a strategic collaboration and license agreement with Genentech, a subsidiary of Roche (RHHBY.US), to co-develop and commercialize COUR's proprietary tolerogenic nanoparticle therapy for the treatment of autoimmune diseases.

Under the terms of the agreement, COUR will receive a $40 million upfront payment and recent milestone payments, in addition to over $900 million in development, commercialization, and sales milestone payments. According to the agreement, COUR will be responsible for completing the early clinical development and technology transfer, while Genentech will take on the clinical development, regulatory filings, and commercialization.

Currently, COUR is conducting a Phase 1b/2a, double-blind, placebo-controlled, multi-center clinical trial for myasthenia gravis, while advancing the development of its candidate drug for type 1 diabetes.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.